AstraZeneca builds pipeline with $232 million Synairgen asthma deal – Reuters


Reuters

AstraZeneca builds pipeline with $232 million Synairgen asthma deal
Reuters
AstraZeneca plans to start a mid-stage Phase IIa study with the drug in early 2015 in patients with severe asthma, building on results from an initial Phase lla trial in a broad asthma population. Severe asthma is a growing focus for major drugmakers
Synairgen shares soar on AstraZeneca asthma dealProactive Investors UK
AstraZeneca licenses rights to Synairgen asthma drugThe West Australian

all 16 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.